Haematology 2018

Cardiovascular disease after therapy for HL: A detailed analysis of 9 collaborative EORTC-LYSA trials Cumulative incidence curves of first cardiovascular disease by LSQ-responder status and for the whole cohort (n=6,039)

A

100

LSQ responder LSQ non-responder Totalcohort

90

LSQ responder

80

70

Total cohort

60

50

40

LSQ non responder

30

Cumulative incidence (%)

20

10

0

0

5

10

15

20

25

30

35

40

Time since treatment start (years)

Numberof patients at risk:

LSQ responder LSQ non-responder Totalcohort

4120 1919 6039

2811

947

348

108

9

3

0

0

1775

1246

668

304

150

56

26

14

4586

2193

1016

412

159

59

26

14

Maraldo et al, Lancet Hemat in 2015

B

50